Literature DB >> 19932232

Surgery for pulmonary coccidioidomycosis: a 10-year experience.

Dawn E Jaroszewski1, Wissam J Halabi, Janis E Blair, Brandon J Coakley, Raymond K Wong, James M Parish, Laszlo T Vaszar, Shimon Kusne, Holenarasipur R Vikram, Paterick A DeValeria, Louis A Lanza, Francisco A Arabia.   

Abstract

BACKGROUND: Coccidioidomycosis results from infection with Coccidioides species endemic to the southwestern United States. The mobile US population has resulted in incremental cases being found throughout the world. The fungal infection can result in pulmonary sequelae, including nodules, cavities, and complications requiring treatment by the thoracic surgeon.
METHODS: A retrospective chart review was conducted of 1,496 patients with coccidioidomycosis treated at our institution (January 1998 to December 2008) to identify those requiring surgery.
RESULTS: Of the 1,496 patients, 86 (6%; mean age, 58 years [range, 18 to 81], 48 women) underwent operations. Radiographs revealed 59 nodules, 18 cavities, 2 infiltrates, and 7 complications of disease (e.g., effusion, pneumothorax, and empyema). Of the 86 patients, 40% underwent resection for persistent symptoms or disease progression despite adequate antifungal therapy. One third of the operations were performed by video-assisted thoracoscopic surgery. Morbidity, 21% (18 patients), and in-hospital mortality, 2% (2 patients), were greater after resection for cavitary lesions with resultant complications versus for nodular disease: 41% versus 12% (p < or = 0.002) and 8% versus 0% (p < 0.005). Prolonged air leaks or bronchopleural fistulas were the most common complications (13 patients). Postoperative antifungal therapy was administered to 42% of patients (89% of cavitary and complicated). There were no cases of recurrence at follow-up (mean, 24 months).
CONCLUSIONS: Surgical intervention was indicated for only a few patients, most commonly for diagnostic dilemmas involving nodular disease, symptomatic nonresponsive cavitary disease, or complications. Prolonged air leaks were the main cause of morbidity. Resection should result in symptom resolution and long-term freedom from recurrence.

Entities:  

Mesh:

Year:  2009        PMID: 19932232     DOI: 10.1016/j.athoracsur.2009.07.075

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

Review 1.  Surgical management of non-mycobacterial fungal infections.

Authors:  Staci Beamer
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 2.  Spontaneous pneumothorax in diffuse cystic lung diseases.

Authors:  Joseph Cooley; Yun Chor Gary Lee; Nishant Gupta
Journal:  Curr Opin Pulm Med       Date:  2017-07       Impact factor: 3.155

Review 3.  Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis.

Authors:  Chinh Nguyen; Bridget Marie Barker; Susan Hoover; David E Nix; Neil M Ampel; Jeffrey A Frelinger; Marc J Orbach; John N Galgiani
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  A case study of imported pulmonary coccidioidomycosis.

Authors:  Zheng-Yang Wang; Sheng-Lan Wen; Ke-Jing Ying
Journal:  J Zhejiang Univ Sci B       Date:  2011-04       Impact factor: 3.066

5.  A 37-Year-Old Man With Pleuritic Chest Pain.

Authors:  Jessica Galant-Swafford; Matthew Light; Mark W Onaitis; Stephen A Rawlings; Joshua Fierer; Judd W Landsberg
Journal:  Chest       Date:  2019-07       Impact factor: 9.410

6.  Risk Factors and Epidemiology of Coccidioidomycosis Demonstrated by a Case of Spontaneous Pulmonary Rupture of Cavitary Coccidioidomycosis.

Authors:  Amy A Yau
Journal:  Case Rep Infect Dis       Date:  2016-01-24

Review 7.  THE TREATMENT OF COCCIDIOIDOMYCOSIS.

Authors:  Neil M Ampel
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-09       Impact factor: 1.846

8.  Top Questions in the Diagnosis and Treatment of Coccidioidomycosis.

Authors:  Fariba M Donovan; Tirdad T Zangeneh; Joshua Malo; John N Galgiani
Journal:  Open Forum Infect Dis       Date:  2017-09-12       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.